|
Eine Ebene nach oben |
Gruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 2
2017
Ake, Julie A.; Schuetz, Alexandra; Pegu, Poonam; Wieczorek, Lindsay; Eller, Michael A.; Kibuuka, Hannah; Sawe, Fredrick; Maboko, Leonard; Polonis, Victoria; Karasavva, Nicos; Weiner, David; Sekiziyivu, Arthur; Kosgei, Josphat; Missanga, Marco; Kroidl, Arne; Mann, Philipp; Ratto-Kim, Silvia; Eller, Leigh Anne; Earl, Patricia; Moss, Bernard; Dorsey-Spitz, Julie; Milazzo, Mark; Ouedraogo, G. Laissa; Rizvi, Farrukh; Yan, Jian; Khan, Amir S.; Peel, Sheila; Sardesai, Niranjan Y.; Michael, Nelson L.; Ngauy, Viseth; Marovich, Mary und Robb, Merlin L.
(2017):
Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost.
In: Journal of infectious Diseases, Bd. 216, Nr. 9: S. 1080-1090
2015
Munseri, Patricia. J.; Kroidl, Arne; Nilsson, Charlotta; Joachim, Agricola; Geldmacher, Christof; Mann, Philipp; Moshiro, Candida; Aboud, Said; Lyamuya, Eligius; Maboko, Leonard; Missanga, Marco; Kaluwa, Bahati; Mfinanga, Sayoki; Podola, Lilly; Bauer, Asli; Godoy-Ramirez, Karina; Marovich, Mary; Moss, Bernard; Hoelscher, Michael; Gotch, Frances; Stoehr, Wolfgang; Stout, Richard; McCormack, Sheena; Wahren, Britta; Mhalu, Fred; Robb, Merlin L.; Biberfeld, Gunnel; Sandstrom, Eric und Bakari, Muhammad
(2015):
Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase IIa Randomized Clinical Trial.
In: PLOS ONE 10(4), e0119629 [PDF, 787kB]
In: PLOS ONE 10(4), e0119629 [PDF, 787kB]